Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05376722
Other study ID # IUNU-PC-111
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date February 22, 2022
Est. completion date September 2024

Study information

Verified date October 2022
Source The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Contact hongqian guo, Dr.
Phone 13605171690
Email dr.ghq@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To evaluate the pathological response rate of pamiparib combined with abiraterone acetate in neoadjuvant therapy for surgically resectable high-risk or very high-risk prostate cancer after radical prostatectomy


Description:

the main purpose: To evaluate the pathological response rate of pamiparib combined with abiraterone acetate in neoadjuvant treatment of surgically resectable high-risk or very high-risk prostate cancer after radical prostatectomy; Note: pathological response rate = pathological complete response rate (pCR) + minimal residual disease (MRD)(defined as residual tumor with the largest crosssection dimension ≤5 mm OR RCB≤0.25CM³) Secondary purpose: 1. To evaluate the safety of pamiparib combined with abiraterone acetate as neoadjuvant therapy for high-risk or very high-risk prostate cancer; 2. To evaluate the rate of PSA biochemical recurrence-free survival (bPFS) at 1 year after radical prostatectomy in neoadjuvant treatment of high-risk or very-high-risk prostate cancer with pamiparib combined with abiraterone acetate; 3. The positive rate of surgical margins in radical prostatectomy; 4. Downstaging rate of radical prostatectomy; 5. Pathological response rate of neoadjuvant patients with HRR gene mutation;


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date September 2024
Est. primary completion date September 2023
Accepts healthy volunteers No
Gender Male
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Inclusion Criteria: 1. Men aged =18 years and =80 years old. 2. Patients with prostate cancer diagnosed by histology or cytology who are suitable for radical prostatectomy. 3. All patients meet at least one of the following criteria: 1. Multiparametric MRI and PSMA PET/CT scan or CT scan showing primary tumor stage = T3; 2. Primary tumor Gleason score = 8; 3. Serum PSA concentration = 20 ng/ml; 4. Imaging assessment has regional lymph node metastasis (N1); 4. Eastern Cooperative Oncology Group (ECOG) performance status score=1 5. Laboratory inspections meet the following requirements: Blood routine: white blood cell count (WBC) =3.0×109/L, platelet count =100×109/L, hemoglobin =9g/dl; renal function: serum creatinine =2×ULN; liver function: alanine aminotransferase (ALT) and Aspartate aminotransferase (AST)=2.5×ULN, total bilirubin TBIL=1.5×ULN; coagulation function: international normalized ratio (INR)<1.5. 6. The subjects participate voluntarily, and the subjects themselves must sign the Informed Consent Form (ICF), indicating that they understand the purpose and required procedures of this research, and are willing to participate in the research. Subjects must be willing and comply with the prohibitions and restrictions set forth in the study protocol. 7. During the treatment, the testosterone level in the blood is reduced to the "castration" level, and the testosterone level is less than 50ng/dL; 8. The subjects can understand and are willing to sign the informed consent Exclusion Criteria: - Exclusion Criteria: 1. Patients with neuroendocrine, small cell, or sarcomatoid features on prostate histopathology. 2. Low- and intermediate-risk localized prostate cancer (all the following conditions are met) (PSA<20 ng/mL; Gleason score<8; clinical stage<T3). 3. Patients with clinical or radiological evidence suggestive of extraregional lymph node metastasis or bone or visceral metastasis (any M1). 4. Received androgen deprivation therapy (including drug or surgical castration) for more than 3 months or focal prostate cancer treatment or prostate cancer radiotherapy and chemotherapy in the past. 5. Patients with severe or uncontrolled concurrent infections. 6. Suffering from New York Heart Association (NYHA) class III/IV congestive heart failure, unstable angina or a history of myocardial infarction within the past 6 months. 7. Uncontrolled severe hypertension, persistent uncontrolled diabetes, oxygen-dependent lung disease, chronic liver disease, or HIV infection. 8. In the past 5 years, other malignancies other than prostate cancer, but cured basal or squamous cell skin cancer can be enrolled. 9. Suffering from mental illness, mental disability or inability to give informed consent.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
pamiparib
pamiparib 40 mg orally, twice a day
abiraterone
biraterone acetate 1000 mg orally, once a day
prednisone
prednisone acetate tablets (prednisone) 5 mg, once a day

Locations

Country Name City State
China Department of Urology, Drum Tower Hospital, Medical School of Nanjing University, Institute of Urology, Nanjing University Nanjing Jiangsu
China Department of Urology, Drum Tower Hospital, Medical School of Nanjing University, Institute of Urology, Nanjing University Nanjing Jiangsu
China The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School Nanjing Jiangsu

Sponsors (4)

Lead Sponsor Collaborator
Hongqian Guo First Affiliated Hospital of Zhejiang University, Nanjing First Hospital, Nanjing Medical University, The First Affiliated Hospital of Soochow University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary the pathological response rate of pamiparib combined with abiraterone acetate in neoadjuvant therapy for surgically resectable high-risk or very high-risk prostate cancer after radical prostatectomy To evaluate the pathological response rate of pamiparib combined with abiraterone acetate in neoadjuvant therapy for surgically resectable high-risk or very high-risk prostate cancer after radical prostatectomy up to 6months
Secondary AEs/SAEs The level of AEs defined by NCI-CTCAE v5.0. Safety assessments will be assessed and documented after initiation of study drug, regardless of relationship to study drug.
The level of complications defined by Clavien-Dindo classification.
Baseline up to 30 days after the last dose of study drug or before initiation of a new antitumor treatment, whichever occurred first
Secondary the 1-year PSA biochemical recurrence-free survival (bPFS) rate after radical prostatectomy in neoadjuvant therapy of paamiparib combined with abiraterone acetate in high- or very-high-risk prostate cancer Defined as the proportion of patients who did not experience biochemical progression or death within 3 years of initiation of pamiparib treatment; biochemical progression was defined as an increase in serum PSA level to >0.2 ng/ml with 2 consecutive increases at least 3 months apart 3 years
Secondary Rate of Positive Surgical Margins The proportion of subjects with positive surgical margins after radical prostatectomy up to 8 months
Secondary Downstaging rate of radical prostatectomy Downstaging rate of radical prostatectomy four months to 2 years after surgery
Secondary Pathological response rate of neoadjuvant patients with HRR gene mutation Pathological response rate of neoadjuvant patients with HRR gene mutation four months to 2 years after surgery
Secondary PSA response rate The proportion of subjects with a =98% reduction in nadir PSA from baseline PSA during neoadjuvant therapy up to 2 years
See also
  Status Clinical Trial Phase
Recruiting NCT05161572 - Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer Phase 2
Not yet recruiting NCT05996484 - Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal Carcinoma Phase 2
Not yet recruiting NCT04520737 - Multimodal Prehabilitation During Chemotherapy in Patients With Colorectal Liver Metastases N/A
Recruiting NCT06138496 - Cadonilimab Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC Phase 2
Not yet recruiting NCT05983094 - Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer Phase 2
Terminated NCT04440982 - Feasibility Study of Intraoperative Detection of Residual Cancer in Breast Cancer Patients Phase 2
Recruiting NCT04028375 - Study of CT and MR in the Gastric Cancer
Active, not recruiting NCT03192735 - Apatinib Combined With SOX Neoadjuvant Therapy for Locally Advanced Gastric Cancer Phase 2
Recruiting NCT04588987 - Neoadjuvant Carilizumab and Apatinib for Recurrent High-Grade Glioma Phase 2
Not yet recruiting NCT05993858 - Neoadjuvant PD-1 Inhibitor Combined With Cetuximab in Operable Locally Advanced HNSCC Phase 2
Active, not recruiting NCT04666090 - Carrelizumab, Chemotherapy and Apatinib in the Neoadjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma Phase 2
Recruiting NCT04848454 - Efficacy and Safety of Combinition of Camrelizumab in Second-line Neoadjuvant Chemotherapy and Adjuvant Therapy Phase 2
Recruiting NCT04062058 - A Phase II Study of Total Neoadjuvant Therapy for Locally Advanced Gastric Cancer Phase 2
Recruiting NCT06124378 - Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer Phase 2
Not yet recruiting NCT06125223 - PABLIXIMAB as Neoadjuvant Therapy for Head and Neck Squamous-cell Carcinoma
Not yet recruiting NCT06404736 - QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer Phase 2
Not yet recruiting NCT06404463 - QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk ER+/HER2- Breast Cancer Phase 2
Recruiting NCT05371197 - Envafolimab as Neoadjuvant Immuntherapy in Resectable Local Advanced dMMR/MSI-H Colorectal Cancer Phase 2
Recruiting NCT06212440 - Clinical Application of Multi-modal Sentinel Lymph Node Staining Method in Breast Cancer Patients After Neoadjuvant Chemotherapy N/A
Completed NCT03178032 - Oncolytic Adenovirus, DNX-2401, for Naive Diffuse Intrinsic Pontine Gliomas Phase 1